Poltreg Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Poltreg's earnings have been declining at an average annual rate of -64.4%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 14% per year.

Belangrijke informatie

-64.4%

Groei van de winst

-52.6%

Groei van de winst per aandeel

Biotechs Groei van de industrie56.3%
Inkomstengroei14.0%
Rendement op eigen vermogen-18.6%
Nettomarge-1,738.6%
Volgende winstupdate21 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Will Poltreg (WSE:PTG) Spend Its Cash Wisely?

Sep 10
Will Poltreg (WSE:PTG) Spend Its Cash Wisely?

Is Poltreg (WSE:PTG) In A Good Position To Invest In Growth?

Mar 13
Is Poltreg (WSE:PTG) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation

Jun 21
Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation

We Think Poltreg (WSE:PTG) Can Afford To Drive Business Growth

Oct 05
We Think Poltreg (WSE:PTG) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation

Jun 16
Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation

Poltreg (WSE:PTG) Is In A Good Position To Deliver On Growth Plans

Feb 24
Poltreg (WSE:PTG) Is In A Good Position To Deliver On Growth Plans

Opbrengsten en kosten

Hoe Poltreg geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

WSE:PTG Opbrengsten, kosten en inkomsten (PLN Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Mar 241-16150
31 Dec 231-14160
30 Sep 231-10150
30 Jun 231-5120
31 Mar 231-290
31 Dec 221-270
30 Sep 221-480
30 Jun 221-480
31 Mar 221-470
31 Dec 211-460
30 Sep 211-240
30 Jun 211-130
31 Mar 211-130
31 Dec 201-130
31 Dec 191-120

Kwaliteitswinsten: PTG is currently unprofitable.

Groeiende winstmarge: PTG is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: PTG is unprofitable, and losses have increased over the past 5 years at a rate of 64.4% per year.

Versnelling van de groei: Unable to compare PTG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: PTG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Rendement op eigen vermogen

Hoge ROE: PTG has a negative Return on Equity (-18.57%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden